Medicus Pharma Ltd. in Philadelphia, announced on September 8, 2026 that it is advancing its transformation into a precision oncology-led biotechnology company, making CD228V, a melanoma-targeted antibody-drug conjugate, its principal strategic priority while shifting other programs toward capital-efficient partnerships. Executive Chairman and CEO Dr. Raza Bokhari said: “Medicus has undergone a significant transformation this year. Our objective is increasingly clear. We are concentrating our capital and organizational resources on programs where we believe focused clinical development and execution may create the greatest value and improve patient outcomes, while using strategic partnerships and other capital-efficient structures to preserve and unlock the potential value of other programs.”
CD228V Becomes the Flagship Program
CD228V is a second-generation CD228-targeted antibody-drug conjugate that uses Pfizer’s established vedotin linker-payload platform to target melanotransferrin (CD228), a protein expressed on solid tumors including melanoma; the release describes it as building on the biological and clinical groundwork of prior-generation versions, though it doesn’t detail the specific nature of Medicus’ arrangement with Pfizer around the platform. The program is already active under a U.S. Investigational New Drug application, with a first-in-human Phase 1 study (NCT06799533) underway; the release doesn’t disclose current enrollment or which tumor types beyond melanoma are being dosed. Medicus says it sees potential to expand CD228V into other CD228-expressing solid tumors beyond its initial melanoma focus.
Narrowing the Rest of the Pipeline
The company is also narrowing SkinJect®, previously aimed at basal cell carcinoma broadly, to focus specifically on Gorlin syndrome, a rare inherited condition that causes patients to develop multiple basal cell carcinomas. Medicus says the narrower indication could position SkinJect for FDA Orphan Drug and Rare Pediatric Disease designations and more favorable rare-disease-anchored pricing; the SKNJCT-005 Phase 2b registrational study is already authorized. Teverelix®, a next-generation GnRH antagonist, keeps its in-house development in acute urinary retention, where Medicus intends to prioritize a roughly 126-patient Phase 2 study, and symptomatic endometriosis, through the Phase 2a PRECISION-E2 study, while Medicus says it will pursue Teverelix’s advanced prostate cancer development specifically through potential partnerships rather than funding it directly.
About Medicus Pharma
Medicus Pharma Ltd. (NASDAQ: MDCX) is described as a precision-guided biotech/life sciences company focused on accelerating the clinical development of novel and potentially disruptive therapeutic assets designed to transform the standard of care, actively engaged in multiple countries across three continents.
According to Medicus, its strategy is to advance select programs through Phase 2 proof-of-concept before pursuing licensing or strategic partnerships with established pharmaceutical companies better positioned to handle late-stage development and commercialization. The company is currently advancing the clinical development of its novel Doxorubicin-containing Microneedle Array (D-MNA) treatment, intended to non-invasively treat basal cell carcinoma of the skin (BCC). Medicus is also developing Teverelix, a next-generation GnRH antagonist, as a potential first-in-class product for acute urinary retention (AURr) and for prostate cancer patients at high cardiovascular risk. Together, D-MNA and Teverelix are said to represent approximately $8 billion in potential market opportunity. https://medicuspharma.com/
